OncoTricks

Rectal cancer without surgery; pausing anticoagulant pills, Nov 18, 2026

Mismatch repair deficient rectal cancer: immunotherapy alone

MLH1PMS2MSH2MSH6

The biopsy is stained for 4 repair proteins. Any one lost = deficient (dMMR). Many mutations, so PD-1 (programmed death 1) blockade works.

Clinical complete response
  • Rectal exam: nothing felt
  • Endoscopy: nothing seen
  • Magnetic resonance imaging (MRI): no tumor
New rectal adenocarcinomaMismatch repair stain on the biopsy, before any plan
All 4 repair proteins present?
Yes
ProficientStandard chemotherapy and chemoradiation, then surgery or watch and wait
Any one lost
DeficientOn the side: germline testing for Lynch syndrome
Stage I or IV
Outside this trialTumor board
Stage II or III
Dostarlimab alone500 mg intravenously every 3 weeks, 9 doses (6 months)
Restage at 6 monthsRectal exam, endoscopy, MRI
All three clean
Complete response: the rectum staysNo chemoradiation, no surgery
SurveillanceExam, endoscopy, MRI and computed tomography (CT) every 4 months (trial schedule)Regrowth: tumor board; chemoradiation and surgery remain possible
Tumor remains or grew
Chemoradiation, then surgery

One dot, one patient: Cercek, N Engl J Med 2025

Rectum, stage II or III

49 of 49complete response

None had the rectum removed. Recurrence-free at 2 years: 96%.

Other organs, stage I to III

35 of 54complete response

33 chose no surgery.

Phase 2, three centers, one drug, no randomized comparison.

The rule

Stain before scalpel.

5 to 10% of rectal cancers are deficient. Deficient: germline testing for Lynch syndrome (inherited mismatch repair defect). Found in 8 of 14 rectal patients tested (Cercek, N Engl J Med 2022).

Sources

PubMed, checked Nov 20, 2026.

  1. Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022. First 12 consecutive patients: 12 of 12 clinical complete response. PubMed 35660797
  2. Cercek A, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025. Other organs: stomach and esophagus, colon, bile ducts and liver, genitourinary, gynecologic. PubMed 40293177

Anticoagulant pills around a procedure

Clot in the last 3 months?
Yes
High clot risk (Douketis, Chest 2022)We postpone what can wait.Clot under 1 month and the procedure cannot wait: call hematology before stopping.After surgery, prophylactic-dose heparin is allowed until the pill restarts (PAUSE).
Bleeding risk of the procedure?Apixaban, rivaroxaban, or dabigatran with creatinine clearance 50 mL/min or more
Low or moderate
Port placement, paracentesis, thoracentesisInterventional radiology often does these without stopping the pill (Patel, J Vasc Interv Radiol 2019): ask the proceduralist.
-4take
-3take
-2take
-1skip
0no dose
+1take
+2take
+3take
High
Percutaneous liver or kidney biopsy, major cancer surgery, spinal or epidural anesthesia, lumbar puncture (we treat it as high)
-4take
-3take
-2skip
-1skip
0no dose
+1skip
+2restart
+3take
Dabigatran, creatinine clearance 30 to 49 mL/min?Yes: the kidney clears it slowly, double the pause
Low or moderate
-4take
-3take
-2skip
-1skip
0no dose
+1take
+2take
+3take
High
-4skip
-3skip
-2skip
-1skip
0no dose
+1skip
+2restart
+3take
No heparin bridge. No drug level.

Day 0: no dose on procedure day. Skip: no pill that day, both doses for apixaban and dabigatran. Restart: day 2 or 3, once bleeding is controlled. Half-life 8 to 14 hours: 1 day off is about 3 half-lives, 2 days about 5. Clearance below 30 (apixaban below 25): not studied in PAUSE, longer pause, ask pharmacy.

PAUSE: pill paused as above 3,007 patients
Major bleeding
under 2%
after high risk
about 3%
Stroke
under 1%
BRIDGE: warfarin, heparin bridge or placebo 1,884 patients
Bleeding, bridge
3.2%
Bleeding, none
1.3%
Stroke, bridge
0.3%
Stroke, none
0.4%
Bridge: more bleeding, no fewer strokes. At 30 days. After high-risk procedures: about 3% with apixaban or rivaroxaban. Douketis, JAMA Intern Med 2019 and N Engl J Med 2015. Atrial fibrillation; the outcome was stroke, not recurrent venous clot. About 9% in PAUSE had active cancer. We borrow the schedule.
Memory trick

1 day low, 2 days high. Dabigatran with weak kidneys: double it.

Sources

PubMed, checked Nov 20, 2026.

  1. Douketis JD, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant (PAUSE). JAMA Intern Med 2019. Major bleeding at 30 days: apixaban 1.35%, dabigatran 0.90%, rivaroxaban 1.85%; after high-risk procedures, apixaban 2.96%, rivaroxaban 2.95%. Stroke or arterial embolism: 0.16%, 0.60%, 0.37%. PubMed 31380891
  2. Douketis JD, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE). N Engl J Med 2015. PubMed 26095867
  3. Douketis JD, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022. PubMed 35964704
  4. Patel IJ, et al. Society of Interventional Radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions, part II. J Vasc Interv Radiol 2019. PubMed 31229333